A method for controlling bleeding from bones, comprising the use of copolymers of oxyethylene and oxypropylene or mixtures thereof to cover the bleeding portions of bones. The copolymers are resorbable by the body, not metabolized, simple to prepare, inexpensive, readily available, and do not interf
A method for controlling bleeding from bones, comprising the use of copolymers of oxyethylene and oxypropylene or mixtures thereof to cover the bleeding portions of bones. The copolymers are resorbable by the body, not metabolized, simple to prepare, inexpensive, readily available, and do not interfere with the fusion, osteogenesis, and related tissue healing and repair of the affected bones.
대표청구항▼
1. A non-toxic, hand-moldable, resorbable bone hemostasis composition consisting of (i) a sterile mixture of copolymers consisting of 75-95% poloxamer code P235 and 5-25% poloxamer code P238, wherein said sterile mixture of copolymers has the consistency of wax at room temperature, and (ii) an optio
1. A non-toxic, hand-moldable, resorbable bone hemostasis composition consisting of (i) a sterile mixture of copolymers consisting of 75-95% poloxamer code P235 and 5-25% poloxamer code P238, wherein said sterile mixture of copolymers has the consistency of wax at room temperature, and (ii) an optional medication to enhance wound healing and accelerate osteogenesis. 2. The non-toxic, hand-moldable, resorbable bone hemostasis composition of claim 1 consisting of said sterile mixture and said medication. 3. The non-toxic, hand-moldable, resorbable bone hemostasis composition of claim 2, wherein said medication to enhance wound healing and accelerate osteogenesis is bone morphogenic protein. 4. A bone hemostasis composition comprising a sterile mixture of copolymers is comprised of 75-95% poloxamer code P235 and 5-25% poloxamer code P238, which is hand moldable at room temperature, in an amount sufficient to stop bleeding when applied to a break or cut in bone. 5. The bone hemostasis composition of claim 4 further comprising a medication. 6. The bone hemostasis composition of claim 5, wherein said medication is selected from the group consisting of antibiotics, analgesics, chemotherapeutic agents, bone anti-resorption factors, bone growth factors, and combinations thereof. 7. The bone hemostasis composition of claim 6, wherein said medication is an antibiotic selected from the group consisting of aminoglycosides, β-lactam antibiotics, cephalosporins, macrolides, penicillines, tetracyclines, quinolones, and sulfonamides. 8. The bone hemostasis composition of claim 6, wherein said medication is an analgesic selected from the group consisting of acetaminophen, non-steroidal anti-inflammatory agents, salicylates, and narcotics. 9. The bone hemostasis composition of claim 6, wherein said medication is carmustine. 10. The bone hemostasis composition of claim 6, wherein said medication is a bone anti-resorption factor selected from the group consisting of risedronate sodium, pamidronate disodium, etidronate disodium, and raloxifene hydrochloride. 11. The bone hemostasis composition of claim 6, wherein said medication is a bone growth factor selected from the group consisting of calcitonin, Tumor Growth Factor Beta, Bone Morphogenic Protein 1, and Bone Morphogenic Protein 2. 12. A method of bone hemostasis comprising: applying to a break or cut in bone such that bleeding is stopped a non-toxic, hand-moldable, resorbable bone hemostasis composition consisting of (i) a sterile mixture of copolymers consisting of 75-95% poloxamer code P235 and 5-25% poloxamer code P238, wherein said sterile mixture of copolymers has the consistency of wax at room temperature, and (ii) an optional medication to enhance wound healing and accelerate osteogenesis. 13. The method of bone hemostasis according to claim 12, wherein said break or cut in bone is due to trauma. 14. The method of bone hemostasis according to claim 12, wherein said break or cut in bone occurs during a surgical procedure. 15. The method of bone hemostasis according to claim 12, wherein a mixture of polyoxyethylene-polyoxypropylene-polyoxyethylene triblock copolymers is applied to said break or cut. 16. The method of bone hemostasis according to claim 12, wherein one polyoxyethylene-polyoxypropylene-polyoxyethylene triblock copolymer is applied to said break or cut. 17. The method of bone hemostasis according to claim 12, wherein said sterile mixture of copolymers is applied with a syringe. 18. A method of bone hemostasis comprising: (a) molding a sterile mixture of copolymers to fit a break or cut in bone, the sterile mixture of copolymers is a non-toxic, hand-moldable, resorbable bone hemostasis composition consisting of (i) a sterile mixture of copolymers consisting of 75-95% poloxamer code P235 and 5-25% poloxamer code P238, wherein said sterile mixture of copolymers has the consistency of wax at room temperature, and (ii) an optional medication to enhance wound healing and accelerate osteogenesis, and(b) applying said molded copolymer or mixture thereof to said break or cut such that bleeding is stopped. 19. The method of bone hemostasis according to claim 18, wherein said break or cut in bone is due to trauma. 20. The method of bone hemostasis according to claim 18, wherein said break or cut in bone occurs during a surgical procedure. 21. The method of bone hemostasis according to claim 18, wherein a mixture of polyoxyethylene-polyoxypropylene-polyoxyethylene triblock copolymers is molded. 22. The method of bone hemostasis according to claim 18, wherein at least one polyoxyethylene-polyoxypropylene-polyoxyethylene triblock copolymer is molded. 23. A method of bone hemostasis comprising application to a break or cut in bone of a sterile, waxy bone hemostasis composition comprising 75-95% poloxamer code P235 and 5-25% poloxamer code P238, which is hand moldable at room temperature, in an amount sufficient to stop bleeding when applied to a break or cut in bone. 24. The method of bone hemostasis according to claim 23, wherein said bone hemostasis composition consists of a mixture of copolymers of oxyethylene and oxypropylene. 25. The method of bone hemostasis according to claim 23, wherein said bone hemostasis composition is molded to fit the break or cut in bone. 26. The method of bone hemostasis according to claim 23, wherein said bone hemostasis composition is applied with a syringe.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (43)
Mattei Frank V. (Piscataway NJ), Absorbable coating composition for sutures.
Mattei Frank V. (Piscataway NJ) Stephenson Martin (Peterborough CAX) Gordon Allin K. (Peterborough CA CAX) Doddi Namassivaya (Upland CA), Absorbable hemostatic composition.
Mattei Frank V. (Piscataway NJ) Stephenson Martin (Peterborough CAX) Gordon Allin K. (Peterborough CA CAX) Doddi Namassivaya (Upland CA), Absorbable hemostatic composition.
Perciaccante Vincent Anthony (Long Island City NY) Landi Henry Patrick (Yorktown Heights NY), Absorbable surgical sutures coated with polyoxyethylene-polyoxypropylene copolymer lubricant.
Chu, Benjamin; Hsiao, Benjamin S.; Fang, Dufei; Brathwaite, Collin, Biodegradable and/or bioabsorbable fibrous articles and methods for using the articles for medical applications.
Jarrett Peter K. (New Haven CT) Jessup George (Brookfield CT) Rosati Louis (Norwalk CT) Martin Chris (Guildford NY AUX) Maney John W. (Spring Valley NY), Coating for tissue drag reduction.
Jarrett Peter K. (New Haven CT) Jessup George (Brookfield CT) Rosati Louis (Norwalk CT) Martin Chris (Guildford NY AUX) Maney John W. (Spring Valley NY), Coating for tissue drag reduction.
Golub Lorne M. (Smithtown NY) Ramamurthy Nangavarum S. (Smithtown NY) McNamara Thomas F. (Port Jefferson NY) Greenwald Robert A. (Melville NY), Composition comprising indomethacin [non-steroidal anti-inflammatory agent]and effectively non-antibacterial tetracyclin.
Kafrawy Adel (Rockaway NJ) Mattei Frank V. (Piscataway NJ) Shalaby Shalaby W. (Lebanon NJ), Copolymers of lactide and/or glycolide with 1,5-dioxepan-2-one.
Tjia Jane S. (Malden MA) Kelley Brian D. (Medford MA) Northey Richard P. (Ipswich MA) Philbrook C. Michael (Boston MA), Formulations for delivery of osteogenic proteins.
Finkenaur Amy L. (Somerville NJ) Cohen Jonathan M. (Marlboro NJ) Shalaby Shalaby W. (Lebanon NJ) Sandoval Elisabeth A. (Irvine CA) Bezwada Rao S. (Whitehouse Station NJ) Kronenthal Richard L. (Fairla, Gel formulations containing growth factors and acrylamide polymer.
Klun, Thomas P.; Dunshee, Wayne K.; Schaffer, Kevin R.; Andrews, Jeffrey F.; Neu, Debra M.; Scholz, Matthew T., Hydrophilic polypropylene fibers having antimicrobial activity.
Williams, Robert O.; Zhang, Feng; Koleng, John J.; Pasternak, Gavril W.; Kolesnikov, Yuri A., Methods and compositions for treating pain of the mucous membrane.
Gary G. Liversidge ; W. Mark Eickhoff ; Kathleen J. Illig ; Pramod Sarpotdar ; Stephen B. Ruddy, Methods for targeting drug delivery to the upper and/or lower gastrointestinal tract.
Landi Henry Patrick (Yorktown Heights NY) Perciaccante Vincent Anthony (Long Island City NY), Non-absorbable surgical sutures coated with polyoxyethylene-polyoxypropylene copolymer lubricant.
Bromberg Lev ; Lupton Elmer Cornelius (E.C.) ; Schiller Matthew E. ; Timm Mary Jo (M.J.) ; McKinney George, Responsive polymer networks and methods of their use.
Hermes Matthew E. (Easton CT) Muth Ross R. (Brookfield CT) Gustafson Darel L. (Shelton CT), Treating bioabsorbable surgical articles by coating with glycerine, polalkyleneoxide block copolymer and gelatin.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.